Corona Remedies Ipo
Corona Remedies IPO Review & Key Points
Review:
Objects of the Issue & Utilisation of proceeds
NA
IPO Lead Managers aka Merchant Bankers
JM Financial Ltd.
IIFL Capital Services Ltd.
Kotak Mahindra Capital Co. Ltd.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 1 | 14 | ₹14,868 |
| Retail Maximum | 13 | 182 | ₹1,93,284 |
| S-HNI Minimum | 14 | 196 | ₹2,08,152 |
| S-HNI Maximum | 67 | 938 | ₹9,96,156 |
| B-HNI Minimum | 68 | 952 | ₹10,11,024 |
| Investor Category | Share Offered | -% Shares |
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | – Shares | 50% |
| NII Shares Offered | – Shares | 15% |
| Retail Shares Offered | – Shares | 35% |
| Anchor Bidding Date | December 5, 2025 |
| Anchor Investors List | |
| Shares Offered | [.] Shares |
| Anchor Size | [.] Cr. |
| lock-in period end date 50% shares (30 Days) | January 10, 2026 |
| lock-in period end date 50% shares (90 Days) | March 11, 2026 |
| IPO Open Date: | December 8, 2025 |
| IPO Close Date: | December 10, 2025 |
| Basis of Allotment: | December 11, 2025 |
| Refunds: | December 12, 2025 |
| Credit to Demat Account: | December 12, 2025 |
| IPO Listing Date: | December 15, 2025 |
| IPO Bidding Cut-off Time: | December 10, 2025 – 5 PM |
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 6,11,60,088 | 72.50% |
| Promoter Holding Post Issue | 6,11,60,088 | -% |
| Period Ended | Revenue | Expense | PAT | Assets |
| 2023 | ₹891.10 | ₹756.07 | ₹84.93 | ₹595.02 |
| 2024 | ₹1,020.93 | ₹859.74 | ₹90.50 | ₹830.58 |
| 2025 | ₹1,202.35 | ₹956.44 | ₹149.43 | ₹929.86 |
| June 2025 | ₹348.56 | ₹276.76 | ₹46.20 | ₹1,012.38 |
| KPI | Values |
| ROE: | 27.50% |
| ROCE: | 41.32% |
| EBITDA Margin: | 20.55% |
| PAT Margin: | 12.49% |
| Debt to equity ratio: | – |
| Earning Per Share (EPS): | ₹24.43 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 24.65% |
| Net Asset Value (NAV): | ₹99.14 |
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Abbott India Limited | 665.62 | 54.28 | 33.41% | 1,992.14 | 6,409.15 Cr. |
| Alkem Laboratories Limited | 181.11 | 32.96 | 18.07% | 1,002.37 | 12,964.52 Cr. |
| Eris Lifesciences Limited | 25.85 | 47.99 | 12.21% | 209.73 | 2,893.64 Cr. |
| GlaxoSmithKline Pharmaceuticals Limited | 54.76 | 83.53 | 47.54% | 115.19 | 3,749.21 Cr. |
| J.B. Chemicals & Pharmaceuticals Limited | 42.45 | 47.21 | 19.21% | 220.88 | 3,917.99 Cr. |
| Mankind Pharma Limited | 49.28 | 54.17 | 13.89% | 352.51 | 12,207.44 Cr. |
| Pfizer Limited | 167.79 | 34.56 | 18.20% | 921.88 | 2,281.35 Cr. |
| Sanofi India Limited | 179.46 | 23.76 | 48.05% | 373.68 | 2,013.20 Cr. |
| Torrent Pharmaceuticals Limited | 56.47 | 66.51 | 25.18% | 224.28 | 11,516.09 Cr. |
| IPO Open Date | December 8, 2025 |
| IPO Close Date | December 10, 2025 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹1008 to ₹1062 Per Share |
| Issue Size | Approx ₹655.37 Crores |
| Offer for Sale: | Approx 61,71,101 Equity Shares |
| Issue Type | Book Built Issue |
| IPO Listing | BSE, NSE |
| DRHP Draft Prospectus | |
| RHP Draft Prospectus |